Publication details

Reply to "Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma. How much is enough?"

Authors	MANDEVILLE Henry C BISOGNO Gianni MINARD-COLIN Veronique ALAGGIO Rita BEN-ARUSH Myriam CHARGARI Cyrus COPPADORO Beatrice CRAIGIE Ross DEVALCK Christine FERMAN Sima FERRARI Andrea GLOSLI Heidi ALVARO Raquel Hladun HOL Marinka MÚDRY Peter ORBACH Daniel ALBIAC Monica Ramos MERKS Johannes H M JENNEY Meriel E M
Year of publication	2025
Type	Article in Periodical
Magazine / Source	Cancer
MU Faculty or unit	Faculty of Medicine
Citation
web	https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35744
Doi	http://dx.doi.org/10.1002/cncr.35744
Keywords	rhabdomyosarcoma; therapy
Description	BACKGROUND The objective of the current study was to determine the characteristic features of sustained responders who develop hepatocellular carcinoma after treatment with interferon for chronic hepatitis C. METHODS This study included 3626 patients with chronic hepatitis C who had received interferon monotherapy. Cox proportional hazards analysis was used to compare sustained responders who did and did not develop hepatocellular carcinoma, and nonsustained responders who developed hepatocellular carcinoma in a multicenter, retrospective cohort study. RESULTS Among 1197 sustained responders, 27 patients developed hepatocellular carcinoma (2.3%). Compared with sustained responders who did not develop hepatocellular carcinoma, patients who developed disease more often were male (P = 0.0212), were older (P = 0.0068), and had advanced-stage histologic disease before interferon therapy (P = 0.0345). Conversely, compared with patients with hepatocellular carcinoma who were not sustained responders, patients who were sustained responders tended to be older at the time of the initiation of interferon therapy (P = 0.0552) and at the time hepatocellular carcinoma was detected (P = 0.0593), and they also were predominantly male (P = 0.0507). The histologic staging and serum aminotransferase levels at the initiation of interferon therapy, the interval to the detection of tumor, and the tumor size showed no significant differences between the two groups. CONCLUSIONS Sustained responders in the group at high risk for developing hepatocellular carcinoma after interferon therapy were older, more often were male, and had more advanced histologic disease stage. Such patients should be followed carefully periodically for > 10 years after they complete interferon therapy.